
Latest
Metabolic research ·
Retatrutide in Canada: Understanding the Clinical Evidence Behind an Investigational Triple-Hormone Receptor Agonist
What the Phase 2 and Phase 3 trials report on retatrutide, the investigational GLP-1 / GIP / glucagon triple agonist: weight, HbA1c and liver-fat results, known side effects, and where it stands with Health Canada.
Read the article : Retatrutide in Canada: Understanding the Clinical Evidence Behind an Investigational Triple-Hormone Receptor Agonist